Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome
Fisher, C.J.; Dhainaut, J.D.; Reines, H.D.; Shelly, M.P.; Thompson, B.W.; Labrecque, J.F.; Catalano, M.A.; Knaus, W.A.; Sadoff, J.C.; Opal, S.M.; Pribble, J.P.; Balk, R.A.; Slotman, G.J.; Iberti, T.J.; Rackow, E.C.; Shapiro, M.J.; Greenman, R.L.
Jama, the Journal of the American Medical Association 271(23): 1836-1843
1994
ISSN/ISBN: 0098-7484 Accession: 077540422
Full Text Article emailed within 1 workday: $29.90
Related References
Tompkins, R.G. 1994: Human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome Critical Care Medicine 22(1): 3Fisher, C.J. 1994: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase IIi rh IL-1ra Sepsis Syndrome Study Group JAMA: The Journal of the American Medical Association 271(23): 1836-1843
Fisher, C.J.; Dhainaut, J.F.; Opal, S.M.; Pribble, J.P.; Balk, R.A.; Slotman, G.J.; Iberti, T.J.; Rackow, E.C.; Shapiro, M.J.; Greenman, R.L. 1994: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase IIi rhIL-1ra Sepsis Syndrome Study Group JAMA 271(23): 1836-1843
Fisher, C.J.Jr.; Dhainaut, J.F.; Pribble, J.P.; Knaus, W.A.; Thompson, R.C.; Group, I. 1ra Phase, II.S.psis Syndrome Study 1993: A phases III multicenter trial of human recombinant interleukin-1 receptor antagonist in treatment of patients with sepsis syndrome Lymphokine and Cytokine Research 12(5): 390
Fisher, C.J.; Slotman, G.J.; Opal, S.M.; Pribble, J.P.; Bone, R.C.; Emmanuel, G.; Ng, D.; Bloedow, D.C.; Catalano, M.A. 1994: Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial Critical Care Medicine 22(1): 12-21
Meyer, N.J.; Reilly, J.P.; Anderson, B.J.; Palakshappa, J.A.; Jones, T.K.; Dunn, T.G.; Shashaty, M.G.S.; Feng, R.; Christie, J.D.; Opal, S.M. 2018: Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration Critical Care Medicine 46(1): 21-28
Noe, L.L.; Pribble, J.P.; Barriere, S.L.; Drummond, M.F.; Hout, B.A.; Bloom, B.S.; Levy, H.; Opal, S.M.; Balk, R.A. 1994: An analysis of hospital length of stay in a double-blind, placebo-controlled clinical trial of recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome Pharmacotherapy 14(3): 371
Bendele, A.M.; Chlipala, E.S.; Rich, W.R.; Edwards, C.K.IIi 1999: Combination benefit of treatment with recombinant human interleukin-1 receptor antagonist and pegylated recombinant human soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis Arthritis and Rheumatism 42(9 Suppl): S171
Slotman, G.J.; Friedman, B.; Brathwaite, C.; Mure, A.J.; Melhorn, L.; Shapiro, E.; Quinn, J.V. 1994: The effects of human recombinant interleukin-1 antagonist on plasma levels of eicosanoids and cytokines in patients with sepsis syndrome Chest 106(2 Suppl): 62S
Pribble, J.P.; FisherCharles, J.Jr.; Opal, S.M.; Balk, R.A.; Slotman, G.J.; Reines, H.D.; Shelly, M.P.; Dhainaut, J.F. A.; Stiles, D.M.; Sadoff, J.C.; Labrecque, J.F.; Campion, G.V.; (Usa), P., II.R. 1ra Sepsis Syndrome Study Group 1994: Recombinant human interleukin-1 receptor antagonist increases survival time in patients with sepsis-induced organ dysfunction Pharmacotherapy 14(3): 355
Boermeester, M.A.; van Leeuwen, P.A.; Schneider, A.J.; Houdijk, A.P.; Ferwerda, C.C.; Wesdorp, R.I. 1993: Interleukin-1 receptor antagonist: a new therapeutic agent in the treatment of sepsis syndrome Nederlands Tijdschrift Voor Geneeskunde 137(7): 337-342
Gordon, G.S.; Fisher, C.F.; Slotman, G.J.; Opal, S.M.; Pribble, J.P.; Stiles, D.M.; Catalano, M.A. 1992: Cost effectiveness of treatment with interleukin 1 receptor antagonist il 1ra in patients with sepsis syndrome Clinical Research 40(2): 254A
Opal, S.M.; Fisher, C.J.; Dhainaut, J.F.; Vincent, J.L.; Brase, R.; Lowry, S.F.; Sadoff, J.C.; Slotman, G.J.; Levy, H.; Balk, R.A.; Shelly, M.P.; Pribble, J.P.; LaBrecque, J.F.; Lookabaugh, J.; Donovan, H.; Dubin, H.; Baughman, R.; Norman, J.; DeMaria, E.; Matzel, K.; Abraham, E.; Seneff, M. 1997: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. the Interleukin-1 Receptor Antagonist Sepsis Investigator Group Critical Care Medicine 25(7): 1115-1124
Rau, R.; Sander, O.; Musikic, P. 1998: Treatment of chronic polyarthritis with a human recombinant interleukin 1 receptor antagonist Zeitschrift für Rheumatologie 57(5): 312-319
Bresnihan, B.; Alvaro-Gracia, J.M.; Cobby, M.; Doherty, M.; Domljan, Z.; Emery, P.; Nuki, G.; Pavelka, K.; Rau, R.; Rozman, B.; Watt, I.; Williams, B.; Aitchison, R.; McCabe, D.; Musikic, P. 1998: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist Arthritis and Rheumatism 41(12): 2196-2204
Kos Golja, M.; Rozman, B.; Watt, I.; Mccabe, D.; Musikic, P. 1999: Treatment with recombinant human interleukin-1 receptor antagonist in rheumatoid arthritis Journal of Autoimmunity (Suppl ): 116
Rau, R.; Sander, O.; Musikic, R. 1998: Treatment of rheumatoid arthritis with a human recombinant interleukin 1 receptor antagonist Zeitschrift fuer Rheumatologie 57(5): 312-319
Conti, P.; Feliciani, C.; Barbacane, R.C.; Panara, M.R.; Reale, M.; Placido, F.C.; Sauder, D.N.; Dempsey, R.A.; Amerio, P. 1992: Inhibition of interleukin-1β mRNA expression and interleukin-1α and β secretion by a specific human recombinant interleukin-1 receptor antagonist in human peripheral blood mononuclear cells Immunology (Oxford) 77(2): 245-250
Suzuki, T. 2002: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist Nihon Rinsho. Japanese Journal of Clinical Medicine 60(12): 2397-2400
Potjo, M.; Theron, A.J.; Cockeran, R.; Sipholi, N.N.; Steel, H.C.; Bale, T.V.; Meyer, P.W.A.; Anderson, R.; Tintinger, G.R. 2019: Interleukin-10 and interleukin-1 receptor antagonist distinguish between patients with sepsis and the systemic inflammatory response syndrome (SIRS) Cytokine 120: 227-233